Alembic Pharmaceuticals has received USFDA tentative approval for its generic Darolutamide tablets used in prostate cancer treatment. The approval applies to the 300 mg strength, positioning Alembic’s product as a generic equivalent to Nubeqa Tablets. With significant demand expected for this category, the company could gain momentum as it moves toward final commercialization.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
